To include your compound in the COVID-19 Resource Center, submit it here.

Vertex starts Phase III of CF triple combo

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) began a Phase III trial to evaluate a triple combination of VX-659, tezacaftor and Kalydeco ivacaftor in 360 cystic fibrosis

Read the full 249 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE